You are here: Home: Audio Program Guide: CCUTT 1 | 2007: CCUTT 1 | 2007 Audio
 
  Go to Management of Colorectal Cancer in the Elderly
Go to Treatment of Metastatic Disease
Go to Hepatic Metastases
Go to Nodal Sampling and Evaluation
Go to Adjuvant Therapy
Go to Rectal Cancer
Go to Novel Clinical Trial Strategies
Go to Challenges in Improving Cancer Outcomes
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
  Management of Colorectal Cancer in the Elderly
  
  Click here to download the entire segment  
Track 1 Use of adjuvant chemotherapy in older patients with colorectal cancer (CRC)
Track 2 Clinical strategies for predicting tolerability of adjuvant chemotherapy in the elderly
Track 3 Impact of side effects on treatment decision-making
     
  Treatment of Metastatic Disease
  
  Click here to download the entire segment  
Track 1 BRiTE observational study of treatment with bevacizumab beyond disease progression in metastatic colorectal cancer (mCRC)
Track 2 Intergroup trial SWOG-S0600 (iBET): Irinotecan-based chemotherapy and cetuximab with or without bevacizumab for patients progressing on first-line therapy
Track 3 Bevacizumab-associated side effects and complications
Track 4 OPTIMOX2: Benefit of maintenance therapy as opposed to complete treatment holidays
Track 5 Benefits of treatment holidays for patients with mCRC
Track 6 Offering patients therapies being evaluated in clinical trials
Track 7 XELOX-1/NO16966: CAPOX or FOLFOX4 with or without bevacizumab as first-line therapy for mCRC
Track 8 FOLFIRI versus FOLFOX as first-line chemotherapy with bevacizumab
Track 9 Patient reactions to alopecia
Track 10 Use of neoadjuvant systemic therapy for patients with potentially resectable liver-only mCRC
Track 11 Generalizability of XELOX-1/NO16966 results to North American patients
Audio
Track 12 Impact of physician approaches to treatment holidays on outcomes in XELOX-1/NO16966
Audio
Track 13 Clinical implications of protocol violations in XELOX-1/NO16966
Audio
Track 14 Continuation of 5-FU/bevacizumab after discontinuing oxaliplatin due to neurotoxicity
Audio
     
  Hepatic Metastases
  
  Click here to download the entire segment  
Track 1 Interval between bevacizumab completion and hepatic surgery
Track 2 Potential mechanism(s) of action of bevacizumab
Track 3 Potential role of bevacizumab as a radiosensitizer
Track 4 Possibility of late toxicity from combined radiation therapy and bevacizumab
Track 5 Algorithms for the management of hepatic metastases
Track 6 Development of the OncoSurge® decision model for resection of CRC hepatic metastases
Track 7 EPOC study evaluating the benefit of perioperative FOLFOX4 chemotherapy for potentially resectable CRC hepatic metastases
Track 8 Clinical implications of EPOC: The use of surgical resection of hepatic metastases with pre- or postoperative chemotherapy
Track 9 Implications of the EPOC trial for future clinical trial investigations

     
  Nodal Sampling and Evaluation
 
  Click here to download the entire segment  
Track 1 Tumor biology, location of nodal retrieval and number of nodes sampled
Track 2 Role of the surgeon in achieving adequate nodal sampling
Track 3 Variability in pathologists’ processing of tumor tissue for nodal evaluation

     
  Adjuvant Therapy
  
  Click here to download the entire segment  
Track 1 Update on the MOSAIC trial of adjuvant FOLFOX
Track 2 ACCENT data set: Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer
Track 3 Survival after recurrence in patients with Stage II and Stage III colon cancer in the ACCENT data set
Track 4 Impact of MOSAIC results on treatment decisions for patients with Stage II CRC
Track 5 Involvement of patients in risk-benefit discussions of adjuvant therapy
Track 6 Factors influencing patient decision-making for modest treatment benefits
Track 7 Surgeons’ referral of patients with Stage II CRC to medical oncologists for discussions about the option for adjuvant therapy
Track 8 Adjuvant therapy for patients with average-risk Stage II CRC
Track 9 Median number of cycles of adjuvant oxaliplatin administration in clinical practice
Track 10 Feasibility of an adjuvant study of dietary and physical activity interventions
Track 11 Appending diet and exercise to future adjuvant trials in a factorial design
Audio
Track 12 Challenges in funding a clinical trial of diet and exercise
Audio
Track 13 Optimizing interventions of diet and exercise for evaluation in clinical trials
Audio
Track 14 Impact of diet and exercise on tumor biology
Audio
     
  Rectal Cancer
  
  Click here to download the entire segment  
Track 1 Clinical endpoints in rectal cancer
Track 2 Acquisition of tumor tissue and correlative science studies in rectal cancer
Track 3 Pathologic complete response as an endpoint in NSABP-R-04
Track 4 Variability in defining and assessing pathologic complete response
Track 5 Incorporation of bevacizumab into clinical trials of neoadjuvant chemoradiation therapy for rectal cancer
Track 6 Neoadjuvant chemoradiation therapy and cetuximab in rectal cancer
Track 7 Use of pathologic complete response rate as a signal for drug development
     
  Novel Clinical Trial Strategies
  
  Click here to download the entire segment  
Track 1 Dual, vertical targeting of the VEGF axis with bevacizumab and the tyrosine kinase inhibitors
Track 2 Evaluation of novel anti-VEGF agents, including AZD2171, after progression on bevacizumab
Track 3 Clinical trial endpoints for the evaluation of biologic agents
     
  Challenges in Improving Cancer Outcomes
  
  Click here to download the entire segment  
Track 1 Incremental advances in cancer treatment
Track 2 Development of novel therapeutics in oncology
Track 3 Evaluating lifestyle and dietary interventions in cancer clinical trials
Track 4 Role of newer agents in colorectal cancer treatment advances
Track 5 Evaluation of patients with “extraordinary outcomes” to stimulate treatment discoveries
Track 6 Facilitating access to screening and treatment to improve cancer outcomes